Cipla donates Rs 25 crores in battle against corona

Published On 2020-04-24 06:25 GMT   |   Update On 2020-04-24 06:25 GMT

New Delhi: Drugs maker Cipla on Tuesday said it has pledged Rs 25 crore to support the government in combating the coronavirus pandemic.This includes a voluntary donation of around Rs 3 crore from Cipla employees who have stepped forward in this hour of national need, the drugmaker said in a regulatory filing.As part of Rs 25 crore, the company has announced a donation of Rs 9 crore to...

Login or Register to read the full article

New Delhi: Drugs maker Cipla on Tuesday said it has pledged Rs 25 crore to support the government in combating the coronavirus pandemic.

This includes a voluntary donation of around Rs 3 crore from Cipla employees who have stepped forward in this hour of national need, the drugmaker said in a regulatory filing.

As part of Rs 25 crore, the company has announced a donation of Rs 9 crore to the PM-CARES Fund, it added.

In addition, the company has announced a donation of Rs 8 crore to various state authorities, Cipla said.

"These contributions will help to further several immediate and long-term relief efforts that the country needs to combat the size and scale of the crisis it is confronted with," it added.

Besides, Cipla Foundation, the social responsibility arm of Cipla, has committed Rs 4 crore towards COVID response programmes, many of which are already underway, the drug's maker said.

The company said it has also allocated Rs 4 crore towards the supply of essentials including medicines, personal protective equipment, sanitisers, masks, gloves and food. 

Read also: Cipla organizes home delivery of its OTC products; ties with Zomato, Swiggy

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News